Traders should monitor the March 9 webcast for interim efficacy and safety signals from the Phase 3 trial; positive data could catalyze significant upside given the high unmet need in CIDP and DNTH's $2.8B market cap.
Price Chart
Executive Summary
Dianthus Therapeutics announced a conference call to discuss interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial of claseprubart in CIDP, scheduled for March 9, 2026. The event is material as it pertains to a key clinical milestone for a Phase 3 program in a severe autoimmune disease, but no results have been disclosed yet.
Key Facts
- Company to discuss interim responder analysis from Part A of the Phase 3 CAPTIVATE trial of claseprubart in CIDP.
- Data discussion scheduled for March 9, 2026, at 8:00 a.m. ET via webcast and conference call.
- No clinical results are released in this announcement — only logistical details for an upcoming event.
- Claseprubart is being evaluated for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a rare and severe autoimmune neurological disorder.
Financial Impact
Potential high impact pending data release, but no financial figures disclosed in this announcement.
Risk Factors
- Interim data may show suboptimal response rates or safety concerns, leading to downside risk.
- Responder analysis is not a primary endpoint and may not predict final trial success.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3251470 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▼ −8.12% | ▼ −6.22% | $89.96 (−19.97%) |
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▼ −8.12% | ▼ −6.22% | $89.96 (−19.97%) |
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▼ −8.12% | ▼ −6.22% | $89.96 (−19.97%) |
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▲ +8.12% | ▲ +6.22% | $89.96 (+19.97%) |
Aug 10, 2026 7w ago | 144 | $108.49 $107.04 | ▼ −1.34% | ▼ −0.28% | $89.96 (−17.08%) |
Jun 29, 2026 13w ago | Press Release | $95.68 $103.87 | ▲ +8.56% | ▲ +8.84% | $89.96 (−5.98%) |
Jun 12, 2026 16w ago | 8-K | $82.07 $97.60 | ▲ +18.92% | ▲ +17.14% | $89.96 (+9.61%) |
Jun 11, 2026 16w ago | Institutional Cluster | $76.45 $100.03 | ▲ +30.84% | ▲ +28.95% | $89.96 (+17.67%) |
May 5, 2026 21w ago | 8-K | $90.42 $84.97 | ▼ −6.03% | ▼ −8.81% | $89.96 (−0.51%) |
Mar 12, 2026 29w ago | Press Release | $77.86 $90.00 | ▲ +15.59% | ▲ +12.00% | $89.96 (+15.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access